RxDoctor Payments Data

Louis Velazquez, PA

Physician Assistant · Greenville, NCNPI 1457387383

Payments from drug & device makers

$383in general payments, 2019–2025

Across 25 payments — averaging $15.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$126
  • Lilly USA, LLC$82
  • Dexcom, Inc.$41
  • Boston Scientific$34
  • VBI Vaccine (delaware) Inc.$26
  • Abbott$19
  • plus $56 from 4 others

What the payments were for

  • Food & beverage$383100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk8$126
Lilly USA, LLC6$82
Dexcom, Inc.3$41
Boston Scientific2$34
VBI Vaccine (delaware) Inc.1$26
Abbott1$19
Impel Pharmaceuticals Inc.1$17
Amgen1$15
AstraZeneca1$12
AbbVie1$12

How this compares

$383 in reported general payments places this provider in the 55th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$12,907
Medicare patients
75
Services billed
278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide20$22,218
JardianceEmpagliflozin24$20,004
MounjaroTirzepatide18$19,111
EliquisApixaban19$11,546
Repatha SureclickEvolocumab13$7,080
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$1,972
Celecoxib16$1,541
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$1,155
Gabapentin54$807
Bumetanide17$788
Albuterol Sulfate HfaAlbuterol Sulfate41$750
Montelukast Sodium34$482
Mirtazapine16$431
Atorvastatin Calcium44$398
Lacosamide12$350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$126$22,21820 claims
Lilly USA, LLCMounjaro$82$19,11118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →